An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Sarepta Therapeutics, Inc. granted equity awards under Nasdaq Listing Rule 5635(c)(4) to 24 new employees in April 2024, comprising options to purchase 0 shares of common stock and 17,090 restricted stock units. The options have an exercise price of $126.66 per share, with vesting schedules spread over four years.
Sarepta Therapeutics, Inc. ha concesso premi azionari a norma del regolamento di quotazione Nasdaq 5635(c)(4) a 24 nuovi dipendenti nell'aprile 2024, comprendendo opzioni per acquistare 0 azioni ordinarie e 17.090 unità di stock riservate. Le opzioni hanno un prezzo di esercizio di $126,66 per azione, con piani di maturazione distribuiti su quattro anni.
Sarepta Therapeutics, Inc. otorgó premios de capital bajo la Norma de Cotización del Nasdaq 5635(c)(4) a 24 nuevos empleados en abril de 2024, que incluyen opciones para comprar 0 acciones comunes y 17,090 unidades de stock restringidas. Las opciones tienen un precio de ejercicio de $126.66 por acción, con cronogramas de vesting que se extienden a lo largo de cuatro años.
Sarepta Therapeutics, Inc.는 2024년 4월에 24명의 새로운 직원들에게 나스닥 상장 규칙 5635(c)(4)에 따라 주식 옵션과 17,090개의 제한 주식 단위를 부여했습니다. 이 옵션들의 행사 가격은 주당 $126.66이며, 4년에 걸쳐 취득 일정이 분포되어 있습니다.
Sarepta Therapeutics, Inc. a attribué des récompenses en actions conformément à la Règle de cotation Nasdaq 5635(c)(4) à 24 nouveaux employés en avril 2024, incluant des options d'achat pour 0 actions ordinaires et 17 090 unités d'actions restreintes. Les options ont un prix d'exercice de 126,66 $ par action, avec des calendriers d'acquisition répartis sur quatre ans.
Sarepta Therapeutics, Inc. hat gemäß Nasdaq-Börsenregel 5635(c)(4) im April 2024 Aktienoptionen für 24 neue Mitarbeiter gewährt, einschließlich Optionen zum Kauf von 0 Stammaktien und 17.090 beschränkten Aktieneinheiten. Die Optionen haben einen Ausübungspreis von $126,66 pro Aktie, mit einem über vier Jahre gestreckten Vesting-Zeitplan.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in April 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 0 shares of Sarepta's common stock, and in the aggregate 17,090 restricted stock units (“RSUs”). The options have an exercise price of $126.66 per share, which is equal to the closing price of Sarepta's common stock on April 30, 2024 (the “Grant Date”). One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the Grant Date and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
How many individuals received inducement grants from Sarepta Therapeutics in April 2024?
Sarepta granted equity awards to 24 individuals hired in April 2024.
What is the exercise price of the options granted to employees by Sarepta Therapeutics?
The exercise price of the options is $126.66 per share.
What is the total number of restricted stock units (RSUs) granted to employees by Sarepta Therapeutics in April 2024?
Sarepta granted a total of 17,090 restricted stock units (RSUs) to employees in April 2024.
What is the vesting schedule for the options and RSUs granted by Sarepta Therapeutics?
The options vest one-fourth on the one-year anniversary of the Grant Date and 1/48th monthly thereafter, fully vesting on the fourth anniversary. The RSUs vest one-fourth yearly, with full vesting on the fourth anniversary.
Under which Nasdaq Listing Rule were the equity awards approved for Sarepta Therapeutics employees?
The equity awards were approved under Nasdaq Listing Rule 5635(c)(4).
